{"database":"GEO","file_versions":[{"files":{"Txt":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE8nnn/GSE8476/suppl/filelist.txt"],"Raw":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE8nnn/GSE8476/suppl/GSE8476_RAW.tar"]},"type":"primary"}],"scores":{"citationCount":1,"reanalysisCount":0,"viewCount":125,"searchCount":5},"additional":{"omics_type":["Transcriptomics","Genomics"],"submitter":["Christina Annunziata"],"instrument_platform":["NCI/Staudt human 15K v13"],"species":["Homo Sapiens"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8476"],"submitter_email":["annunzic@mail.nih.gov"],"submitter_affiliation":["Center for Cancer Research"],"repository":["GEO"],"reanalysis_count":["0"],"citation_count_scaled":["0.0022271714922048997"],"reanalysis_count_scaled":["0.0"],"view_count_scaled":["0.03973299427844883"],"download_count_scaled":["0.0"],"view_count":["125"],"name_synonyms":["Plasma-Cell Myelomas, Disease, Myelomas, Myeloma, Multiple myeloma (disorder), Kahler's disease, Multiple myeloma without mention of having achieved remission, Cell Myelomas, inhibitor of NF-kappaB kinase activity, IKBKB, IKBKA, TBK1, STK12, Myeloma Multiple, ikappaB kinase activity., Myeloma-Multiples, Myeloma-Multiple, MM, multiple myeloma, Kahler, Multiple Myelomas, CHUK, [M]Plasma cell myeloma, Myelomatoses, NOS, Myelomatosis, MULT MYELM W/O REMISSION, morphology (morphologic abnormality), Plasma-Cell, Plasma-Cell Myeloma, Plasmacytic myeloma, Plasma, inhibitor of NFkappaB kinase activity, MULT MYE W/O ACHV RMSON, Multiple myeloma, NFkB, Plasma Cell Myelomas, myeloma, Kahler Disease, TANK-binding kinase 1 activity, ATP:IkappaB protein phosphotransferase activity, Multiple myeloma without mention of remission, Multiple, no ICD-O subtype, Cell Myeloma, IKK, Plasma Cell Myeloma, IKK-2, no ICD-O subtype (morphologic abnormality), IKK-1, Multiple myeloma (clinical), Plasma Cell, Kahler disease"],"description_synonyms":["Organic Mental Disorders, rIAP1, DIMETHYL SULFOXIDE, target gene, CRAF1, S(O)Me2., NFKB-p50, Substance-Induced, Cell Myelomas, AIP1, Dependence, congenital defects, mcIAP1, Myeloma-Multiples, Myeloma-Multiple, aplasia, Mutations, NFKBIKB, NFKBIKA, Line, LAP1, Conserved helix-loop-helix ubiquitous kinase, Transcription factor 16, time_series_design, T-BAM, AU045934, treatment, CYLDI, HAIP1, human disease, cIAP2, cIAP1, cIAP-2, cIAP-1, Drug Addiction, hypoplasia, dimethyl sulphoxide, myeloma, DRUG USE DIS, elevated, Substance, CYLD1, Epigenomic, CVID10, KBF1, Abuse, high frequency, Cell Myeloma, Hiap-2, no ICD-O subtype (morphologic abnormality), signaling process, NF-kappaB2, NF-kappaB1, CIAP2, Substance Addiction, disease management, Homo sapiens disease, associated, Plasma Cell, Dimethylsulfoxid, single organism signaling, Plasma-Cell Myelomas, CD40, keywords, DMSO, lyt, Myelomas, dimethyli sulfoxidum, dmso, AW107670, Myeloma, USPL2, Tnfrsf5, methylsulfinylmethane, Substance Use, IKK-beta, MIAP2, MIAP1, deformities, LYT10, IkBKA, CAP1, Substance Use Disorders, Kahler, AW146227, p50B, (CH3)2SO, Substance Use Disorder, NFKB-p105, mKIAA0849, BRSS, Diseases, IMD3, NOS, Substance-Related Disorders, morphology (morphologic abnormality), Plasma-Cell Myeloma, Lines, Drug Use, atresia, CDW40, (methanesulfinyl)methane, p50|p105, Nuclear factor NF-kappa-B inhibitor kinase alpha, Epigenetic, Habituation, malformations, AI528849, IAP2, AI326936, IAP1, H2TF1, TCF-16, NF-kappa-B, CDw40, Multiple,, IKK-2, anomalies, Substance Induced, IGM, Protein Stabilities, p49, Addiction, Multiple myeloma (clinical), Epigenetics, IKK-A, Kahler disease, biological signaling, NF-kB, NF-kappaB, p50, TRAP, HS, Abuses, p52, Multiple myeloma (disorder), Kahler's disease, Multiple myeloma without mention of having achieved remission, Rp1h, dimethylsulfoxyde, MEKKK4, CD40L receptor, C2H6OS, HSNIK, CAP-1, TNFRSF5, IKK[b], Stability, Multiple Myelomas, Drug Usage, EAC, RNF48, RNF49, IKKbeta, HGK, [M]Plasma cell myeloma, GP39, NF-KB1, Myelomatoses, IkappaB kinase, defects, 2010013M14Rik, AI132552, RGD1307189, FTDCR1B, Plasmacytic myeloma, sulfinylbis(methane), Multiple myeloma, NF-kB2, Substance Abuse, NF-kB1, Plasma Cell Myelomas, IIAE5, HIAP1, FLH21957, HIAP2, I-kappa-B kinase 1, Usage, dimetil sulfoxido, API2, Drug Use Disorders, Api2, Api1, API1, SUBSTANCE RELATED DIS, Drug Habituation, Disorder, 9430080K19Rik, HIGM1, high elevation, CD40bp, C130039D01Rik, Disease, data, HEL-S-31, Birc3, Birc2, B-cell surface antigen CD40, Cell Lines, Rp1, MFT1, Bp50, Myeloma Multiple, Drug Use Disorder, Cell, LRRGT00003, MM, Stabilities, multiple myeloma, Drug Abuse, 2900009M21Rik, addiction, c-IAP2, ORGANIC MENTAL DIS SUBSTANCE INDUCED, agenesis, Protein, aly, c-IAP1, MIHB, p100, MIHC, Myelomatosis, p105, Dimethyl sulfoxide, IKK-alpha, Substance Dependence, p49|p100, MULT MYELM W/O REMISSION, Plasma-Cell, NFkappaB, Plasma, amn, MULT MYE W/O ACHV RMSON, frequent, IKK1, IKK2, MALT2, dimethyl sulfoxide, Kahler Disease, patient, CDMT, MFT, IKKB, EBP-1, AW046177, signalling, Multiple myeloma without mention of remission, macromolecular stability of protein, Drug, AU043147, SBS, no ICD-O subtype, SUBSTANCE USE DIS, signalling process, Plasma Cell Myeloma, DEL, I-kappa-B kinase alpha, IMD15, birth defects, NIK, Nik, LYT-10, dimethyl sulfur oxide, Substance Abuses, TEM"],"citation_count":["1"],"search_count":["5"],"search_domains":["patentfamilies~0","rfam~0","merops~0","complex-portal~0","uniprot~0","wormbaseparasite~0","reactome~0","emdb~0","wgs_masters~0","ebiweb_resources~0","ipd-mhc~0","taxonomy~0","genome_assembly~0","ebiweb_people~0","enzymeportal_enzymes~0","pdbe~0","chebi~0","patentproteins~0","interpro7~0","uniref~0","chembl~0","gpcrdb~0","hgnc~0","intact~0","rhea~0","imgt-hla~0","patentnucleotides~0","ensemblroot~0","europepmc~1","non-coding~0","pubmed~1","identifiers_registry~0","pdbechem~0","biosamples~0","interpro~0","biotools~0","mesh~0","coding~0","sra~0","efo~0","human_diseases~0","embl~0","treefam~0","uniparc~0","project~3","ols~0","dgva~0","intenz~0","go~0","tsa_masters~0","ebiweb_corporate~0","omim~0","sbo~0","lrg~0","ipd-kir~0","rnacentral~0","orcid_data_claims~0","metagenomics~0","pfam~0"],"additional_accession":[]},"is_claimable":false,"name":"NFkB in multiple myeloma - L363 IKK inhibitor","description":"Mechanisms of constitutive NF-kappaB signaling in multiple myeloma are unknown. An inhibitor of IkappaB kinase beta (IKKbeta), targeting the classical NF-kappaB pathway, was lethal to many myeloma cell lines. Several had elevated expression of NIK due to genomic alterations or enhanced protein stability while others had inactivating mutations or deletion of TRAF3. Both abnormalities triggered the classical and alternative NF-kappaB pathways. A majority of primary myeloma patient samples and cell lines had elevated NF-kappaB target gene expression, often associated with genetic and epigenetic alteration of NIK, TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, and NFKB2. These genetic and functional data demonstrate that addiction to the NF-kappaB pathway is a frequent feature of myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease. Keywords: time series design Overall design: L363 cells were treated with IKKb inhibitor MLN120b for 8h, 12h, 24h. Three timecourses, a total of 8 samples, were analyzed in comparison to cells treated with DMSO (solvent) alone.","dates":{"publication":"2007-10-29","submission":"2007-07-13"},"accession":"GSE8476","cross_references":{"pubmed":["17692804"]}}